Pharma major Lupin has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing plant in Nagpur on Monday.
The US health regulator issues an EIR to a company when an inspection is satisfactorily closed.
The health regulator had inspected the company's Nagpur manufacturing facility between January 6 and January 10, 2020, Lupin Ltd said in a statement.
"We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid